• PBI is an agonist of GPR and

  2022-09-07

  

  PBI-4050 is an agonist of GPR40 and acts as an antagonist or inverse agonist of GPR84. It cannot be excluded that other targets besides GPR40 and GPR84 could be implicated in the mechanism of action of PBI-4050 and could be explored in future studies. However, the present study, and in particular th

• In regards to animals several studies have

  2022-09-07

  

  In regards to animals, several studies have reported the peroxisomal localization of FPS (Krisans et al., 1994, Olivier et al., 2000, Kovacs et al., 2007). Transfections of mammalian cells with the rat short FPS isoform followed by immunodetection localized the enzyme to the peroxisome (Olivier et a

• FDP is considered as key intermediate in the isoprenoid bios

  2022-09-07

  

  FDP is considered as key intermediate in the isoprenoid biosynthetic pathway, since it is the common precursor of polyisoprene units and farnesylated proteins (Cao et al., 2012). In order to understand the role of FDP gene in rubber-producing plants it is of critical importance to venlafaxine hydroc

• The Rho family of GTPases is composed of many small

  2022-09-07

  

  The Rho family of GTPases is composed of many small ubiquitous signaling G proteins that bind to guanosine triphosphate (GTP) and hydrolyze it to guanosine diphosphate (GDP). They act as switches: when binding to GTP, they are active and associate with a variety of target proteins that regulate intr

• br Factor Xa an enzyme in

  2022-09-07

  

  Factor Xa, an enzyme in the coagulation cascade, has recently been identified as having a role in inflammation, generating interest in factor Xa inhibitors as anti-inflammatory agents beyond their established use as anticoagulants [, , , ]. We report sustained clinical and electrophysiologic impro

• A small number of patients had accessory

  2022-09-07

  

  A small number of patients (11%) had accessory integrase mutations (E157Q, G163R, L74IM, and/or V151I) that confer potential or low-level resistance and generally only when they occur in combination with other high/intermediate level resistance mutations. This is a somewhat higher incidence than tha

• The H R antagonist cimetidine Tagamet became the first billi

  2022-09-07

  

  The H2R antagonist cimetidine (Tagamet™) became the first billion-dollar drug in the 1980s for the treatment of peptic ulcer disease. Other H2R antagonists include ranitidine, famotidine, nizatidine, and zolantidine, the latter showing good BBB penetration with a steady-state brain/blood ratio of 1.

• The H R antagonist JNJ

  2022-09-07

  

  The H3R antagonist JNJ-17216498, developed by Johnson & Johnson, has entered clinical trial studies, but no information regarding its structure has been publicized to date. A phase II study of JNJ-17216498 monotherapy has been completed for patients with narcolepsy, but the results are not publicall

• Imiquimod hydrochloride Introduction As a compound class his

  2022-09-07

  

  Introduction As a compound class, histone deacetylase inhibitors (HDIs) have been remarkably successful in the treatment of T-cell lymphoma [1]. Vorinostat (suberanilohydroxamic Imiquimod hydrochloride or SAHA) was approved by the FDA in 2006 for the treatment of cutaneous T-cell lymphoma [2], [3]

• Among the GSK inhibitors available

  2022-09-06

  

  Among the GSK-3 inhibitors available in market, lithium is probably the only example and the oldest one. Some molecules, both natural and synthetic, such as maleimide derivatives, staurosporine (from the bacterium Streptomyces storosporeus), indole derivatives such as indirubin (used since long in t

• Lactate induced GPR activation was confirmed with a

  2022-09-06

  

  Lactate-induced GPR81 activation was confirmed with a fluorimetric imaging plate reader (FLIPR) assay, in which lactate induced a [Ca2+] flux in CHO cells stably expressing Gqi5 and HA-GPR81 but not vector control (Fig. 1C). The EC50 of lactate in the FLIPR assay was 4.3±0.73mM, a value well within

• Several studies have found that GPR possesses a distinct

  2022-09-06

  

  Several studies have found that GPR55 possesses a distinct pharmacology from that of CB1 and CB2, and that only certain cannabinoids act at this receptor. In transfected SMER 3 expressing hGPR55, out of more than 20 synthetic and endogenous cannabinoids evaluated, only 2 compounds, SR141716A (Rimon

• br TGR Agonists br FXR

  2022-09-06

  

  TGR5 Agonists FXR/TGR5 Dual Agonists In 2010, a FXR/TGR5 dual agonist, 51 (INT-767), was reported [57]. Using an AlphaScreen coactivator recruitment assay, the potency of 51 at FXR was 30nM. In NCI-H716 cells, 51 stimulated intracellular cAMP secretion with an EC50 of 0.63μM. Its TGR5 potency

• MAPK are involved in a large variety of solid

  2022-09-03

  

  MAPK are involved in a large variety of solid and hematolgical neoplasms and, indeed, several components of the MAPK network have already been proposed as targets in cancer therapy, such as p38, JNK, ERK1/2, MEK1/2, RAF, RAS, DUSP1 and ERK5 [11], [12]. Among them, alteration of the RAS-RAF-MEK1/2-ER

• br Acknowledgements br Introduction Ghrelin is a potent

  2022-09-03

  

  Acknowledgements Introduction Ghrelin is a potent orexigenic hormone and growth hormone secretagogue mainly derived from the stomach [1], [2], [3], [4], [5]. Other pleiotropic actions of the hormone include those that are glucoregulatory, food reward-enhancing, gastric motility-enhancing, and

15800 records 356/1054 page Previous Next First page 上5页 356357358359360 下5页 Last page